12:56:04 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-15 Kvartalsrapport 2025-Q1
2025-01-15 Årsstämma 2025
2024-10-09 Bokslutskommuniké 2024
2024-07-10 Kvartalsrapport 2024-Q3
2024-04-10 Kvartalsrapport 2024-Q2
2024-01-11 Ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10 Årsstämma 2024
2024-01-10 Kvartalsrapport 2024-Q1
2023-10-11 Bokslutskommuniké 2023
2023-07-14 Kvartalsrapport 2023-Q3
2023-04-12 Kvartalsrapport 2023-Q2
2023-01-12 Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.
2023-08-23 08:00:00

A new strategic partnership with a global pharmaceutical company underpins the strategic ambition of being a local champion and provides Newbury exclusive access to marketing of several pharmaceutical products used in hospitals across the Nordic region. This opens for a new business area within the hospital segment in addition to the existing portfolio which is focused on specialty prescription medicine in the pharmacy segment.

Newbury enters the Nordic hospital market through a strategic partnership with a global pharmaceutical company. The partnership is based on an ambition of expanding the portfolio of medicines to become a key player in the hospital segment and can consist of branded and non-branded products.

Newbury is getting access to a portfolio of hospital products from this new strategic partnership where Newbury will represent the global pharmaceutical partner in the Nordic region. The partnership will initially focus on registration of a few selected products which will be launched in line with approval from the authorities.

“We are excited to announce this partnership which is a testimony to our strategic ambition of being a local champion and alternative partner to global players in the Nordic region. Furthermore, we gain access to a variety of products which over time can be registered in the Nordics. This is a blue-print of Newbury as a trusted and committed partner and we look forward to unfold this new segment to our business.”.

The new strategic partnership is expected to contribute with sales growth after the regulatory approvals have been obtained during 2024/2025 and is based on a distribution agreement with limited future investments for Newbury.